Cadrenal Therapeutics Reports $10.2 Million Net Loss and Deteriorating Cash Position

Cadrenal Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $10.2 million for the nine months ended September 30, 2025, compared to a loss of $6.5 million during the same period in 2024, marking a 46% increase in losses. Operating expenses surged to $10.4 million, a 56% increase from $6.7 million in the prior year, primarily driven by a 73% rise in general and administrative expenses, which reached $7.0 million. Research and development expenses also increased by 29% to $3.4 million, reflecting ongoing investments in clinical development.

The company’s cash position has deteriorated, with cash and cash equivalents dropping to $3.9 million as of September 30, 2025, down from $10.0 million at the end of 2024. This decline is attributed to cash used in operating activities totaling $10.0 million during the nine-month period, which was significantly higher than the $5.6 million used in the same timeframe the previous year. Cadrenal's accumulated deficit has now reached $35.9 million, raising concerns about its ability to sustain operations without additional funding.

In terms of strategic developments, Cadrenal recently acquired assets from eXIthera Pharmaceuticals, including a portfolio of investigational Factor XIa inhibitors, which could enhance its product pipeline. The acquisition, finalized on September 12, 2025, involved an initial payment of $50,000, with potential milestone payments totaling up to $15 million based on future clinical developments. This move is part of Cadrenal's strategy to expand its offerings in the anticoagulation market, particularly with its lead product candidate, tecarfarin, which is designed for patients with specific cardiovascular conditions.

Operationally, Cadrenal has seen fluctuations in its engagement metrics, with a notable increase in its employee headcount, reflecting its growth strategy. The company sold 236,728 shares through its at-the-market facility during the nine months ended September 30, 2025, generating approximately $4.0 million in gross proceeds. However, the company anticipates that its existing cash resources will not be sufficient to meet its operational and capital requirements for the next 12 months, prompting plans to seek additional funding through equity offerings or strategic partnerships.

Looking ahead, Cadrenal's management has expressed uncertainty regarding its ability to continue as a going concern, emphasizing the need for additional capital to support its ongoing development programs. The company is actively exploring options to raise funds, but there is no assurance that it will be able to secure financing on favorable terms. The financial outlook remains precarious, with the potential for operational delays or reductions if funding is not obtained.